Home LiteratureArticle Details
PMID: 23884378 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Nature reviews. Cancer ·Vol. 13 ·No. 9 ·2013-09-00 ·Pages 637-51

Rosanò L, Spinella F, Bagnato A

Abstract

Activation of autocrine and paracrine signalling by endothelin 1 (ET1) binding to its receptors elicits pleiotropic effects on tumour cells and on the host microenvironment. This activation modulates cell proliferation, apoptosis, migration, epithelial-to-mesenchymal transition, chemoresistance and neovascularization, thus providing a strong rationale for targeting ET1 receptors in cancer. In this Review, we discuss the advances in our understanding of the diverse biological roles of ET1 in cancer and describe the latest preclinical and clinical progress that has been made using small-molecule antagonists of ET1 receptors that inhibit ET1-driven signalling.

MeSH Terms
Autocrine Communication Cell Proliferation Cell Survival Endothelin-1/antagonists & inhibitors,metabolism Humans Lymphangiogenesis Neoplasms/drug therapy,metabolism Neovascularization, Pathologic/metabolism Paracrine Communication Receptors, Endothelin/metabolism Signal Transduction Tumor Microenvironment
Chemicals
Endothelin-1 Receptors, Endothelin
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Rosanò Laura
Laboratory of Molecular Pathology A, Regina Elena National Cancer Institute, Via Elio Chianesi 53, Rome 00144, Italy.
Spinella Francesca
Bagnato Anna
References (149)
149 references, click to expand
  1. Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways.
    Life Sci. 2012 Oct 15;91(13-14):544-9 PMID: 22480514
  2. Macitentan (ACT-064992), a tissue-targeting endothelin receptor antagonist, enhances therapeutic efficacy of paclitaxel by modulating survival pathways in orthotopic models of metastatic human ovarian cancer.
    Neoplasia. 2011 Feb;13(2):167-79 PMID: 21403842
  3. Identification of Endothelin-1 and NR4A2 as CD133-regulated genes in colon cancer cells.
    J Pathol. 2011 Oct;225(2):305-14 PMID: 21826669
  4. Functional endothelin ET B receptors are selectively expressed in human oligodendrogliomas.
    Brain Res Mol Brain Res. 2005 Jun 13;137(1-2):77-88 PMID: 15950764
  5. Expression and prognostic relevance of endothelin-B receptor in vulvar cancer.
    Oncol Rep. 2007 Aug;18(2):305-11 PMID: 17611649
  6. Endothelin B receptor blockade inhibits dynamics of cell interactions and communications in melanoma cell progression.
    Cancer Res. 2004 Feb 15;64(4):1436-43 PMID: 14973117
  7. Expression of endothelin 1 and endothelin A receptor in HPV-associated cervical carcinoma: new potential targets for anticancer therapy.
    FASEB J. 2000 Nov;14(14):2277-83 PMID: 11053249
  8. Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo.
    Clin Cancer Res. 2005 Mar 1;11(5):1798-808 PMID: 15756002
  9. Targeting endothelin A receptor enhances anti-proliferative and anti-invasive effects of the HER2 antibody trastuzumab in HER2-overexpressing breast cancer cells.
    Int J Cancer. 2010 Aug 1;127(3):696-706 PMID: 19960438
  10. Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization.
    Cancer Res. 2007 Jul 1;67(13):6163-73 PMID: 17616673
  11. A role for endothelin-2 and its receptors in breast tumor cell invasion.
    Cancer Res. 2004 Apr 1;64(7):2461-8 PMID: 15059899
  12. Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for Akt activation.
    Mol Pharmacol. 2002 Mar;61(3):524-32 PMID: 11854432
  13. Decreased endothelin receptor B expression in large primary uveal melanomas is associated with early clinical metastasis and short survival.
    Br J Cancer. 2002 Nov 18;87(11):1308-13 PMID: 12439722
  14. Endothelin-2 is a hypoxia-induced autocrine survival factor for breast tumor cells.
    Mol Cancer Ther. 2002 Dec;1(14):1273-81 PMID: 12516960
  15. Endothelin-1 stimulates motility of head and neck squamous carcinoma cells by promoting stromal-epithelial interactions.
    Int J Cancer. 2012 Jan 1;130(1):40-7 PMID: 21491424
  16. Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.
    Am J Pathol. 2010 Aug;177(2):1004-16 PMID: 20616339
  17. Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
    Cancer Res. 2007 Jul 1;67(13):6351-9 PMID: 17616694
  18. The epithelial-mesenchymal transition generates cells with properties of stem cells.
    Cell. 2008 May 16;133(4):704-15 PMID: 18485877
  19. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate.
    Nat Med. 1995 Sep;1(9):944-9 PMID: 7585222
  20. Endothelin-B receptor activation triggers an endogenous analgesic cascade at sites of peripheral injury.
    Nat Med. 2003 Aug;9(8):1055-61 PMID: 12847519
  21. Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.
    Transl Oncol. 2012 Feb;5(1):39-47 PMID: 22348175
  22. Endothelin-1 induces the transactivation of vascular endothelial growth factor receptor-3 and modulates cell migration and vasculogenic mimicry in melanoma cells.
    J Mol Med (Berl). 2013 Mar;91(3):395-405 PMID: 22965194
  23. Endothelins and hypoxia-inducible factor in cancer.
    Endocr Relat Cancer. 2007 Jun;14(2):233-44 PMID: 17639040
  24. Endothelin-1 stimulates lymphatic endothelial cells and lymphatic vessels to grow and invade.
    Cancer Res. 2009 Mar 15;69(6):2669-76 PMID: 19276384
  25. Pathway analysis of gene lists associated with platinum-based chemotherapy resistance in ovarian cancer: the big picture.
    Gynecol Oncol. 2010 May;117(2):170-6 PMID: 20132968
  26. Integrin-linked kinase functions as a downstream mediator of endothelin-1 to promote invasive behavior in ovarian carcinoma.
    Mol Cancer Ther. 2006 Apr;5(4):833-42 PMID: 16648553
  27. Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells.
    Cancer Biol Ther. 2013 Feb;14(2):184-92 PMID: 23192269
  28. Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.
    Cancer Res. 2009 May 15;69(10):4260-9 PMID: 19417139
  29. Epigenetic control of endothelin-1 axis affects invasiveness of breast carcinoma cells with bone tropism.
    Exp Cell Res. 2013 Jul 15;319(12):1865-1874 PMID: 23660387
  30. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.
    Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6213s-6216s PMID: 17062703
  31. NFIB is a governor of epithelial-melanocyte stem cell behaviour in a shared niche.
    Nature. 2013 Mar 7;495(7439):98-102 PMID: 23389444
  32. Endothelins induce CCR7 expression by breast tumor cells via endothelin receptor A and hypoxia-inducible factor-1.
    Cancer Res. 2006 Dec 15;66(24):11802-7 PMID: 17178876
  33. Neutral endopeptidase 24.11 loss in metastatic human prostate cancer contributes to androgen-independent progression.
    Nat Med. 1998 Jan;4(1):50-7 PMID: 9427606
  34. Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers.
    Clin Cancer Res. 2005 Sep 1;11(17):6300-10 PMID: 16144934
  35. Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis.
    Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2806-11 PMID: 19202075
  36. A phase II study of bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma.
    Invest New Drugs. 2007 Jun;25(3):247-52 PMID: 17021960
  37. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors.
    J Neurooncol. 2009 Aug;94(1):1-19 PMID: 19468690
  38. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo.
    Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11496-500 PMID: 10500205
  39. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo.
    Am J Pathol. 2000 Nov;157(5):1703-11 PMID: 11073829
  40. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.
    Cancer Metastasis Rev. 2011 Mar;30(1):141-51 PMID: 21298574
  41. Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role.
    Eur J Cancer. 2006 Mar;42(5):680-7 PMID: 16439111
  42. Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma.
    Mol Cancer Ther. 2006 Jun;5(6):1483-92 PMID: 16818507
  43. Expression of the endothelin-B receptor in pigment cell lesions of the skin. Evidence for its role as tumor progression marker in malignant melanoma.
    Virchows Arch. 2001 May;438(5):485-91 PMID: 11407477
  44. CD31, EDNRB and TSPAN7 are promising prognostic markers in clear-cell renal cell carcinoma revealed by genome-wide expression analyses of primary tumors and metastases.
    Int J Cancer. 2012 Sep 1;131(5):E693-704 PMID: 22213152
  45. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer.
    Cancer Res. 2007 Apr 15;67(8):3818-26 PMID: 17440096
  46. Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
    Cancer Res. 2003 May 15;63(10):2447-53 PMID: 12750265
  47. Endothelin B receptor agonist, IRL 1620, enhances the anti-tumor efficacy of paclitaxel in breast tumor rats.
    Breast Cancer Res Treat. 2005 Dec;94(3):237-47 PMID: 16244791
  48. Stimulation or endothelin-1 secretion by human breast cancer cells through protein kinase A activation: a possible novel paracrine loop involving breast fibroblast-derived prostaglandin E2.
    Mol Cell Endocrinol. 1997 Feb 7;126(2):143-51 PMID: 9089652
  49. The endothelin system in human glioblastoma.
    Lab Invest. 2000 Nov;80(11):1681-9 PMID: 11092528
  50. Endothelin-1 gene regulation.
    FASEB J. 2011 Jan;25(1):16-28 PMID: 20837776
  51. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer.
    Cancer. 2007 Nov 1;110(9):1959-66 PMID: 17886253
  52. Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells.
    Cancer Res. 2007 Feb 15;67(4):1725-34 PMID: 17308114
  53. Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells.
    Clin Cancer Res. 1995 Sep;1(9):1059-66 PMID: 9816080
  54. Altered endothelin receptor subtypes in colorectal cancer.
    Eur J Gastroenterol Hepatol. 2007 Sep;19(9):775-82 PMID: 17700263
  55. Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer.
    Clin Cancer Res. 2004 Apr 1;10(7):2393-400 PMID: 15073116
  56. Expression of endothelin-1, endothelin-A, and endothelin-B receptor in human breast cancer and correlation with long-term follow-up.
    Clin Cancer Res. 2003 Sep 15;9(11):4125-31 PMID: 14519635
  57. MicroRNA-1 inhibits proliferation of hepatocarcinoma cells by targeting endothelin-1.
    Life Sci. 2012 Oct 5;91(11-12):440-447 PMID: 22963810
  58. IRL-1620, an endothelin-B receptor agonist, enhanced radiation induced reduction in tumor volume in Dalton's Lymphoma Ascites tumor model.
    Arzneimittelforschung. 2012 Jan;62(1):14-7 PMID: 22331757
  59. A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer.
    Cancer Chemother Pharmacol. 2011 May;67(5):1203-8 PMID: 21153822
  60. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer.
    J Clin Invest. 2011 Jan;121(1):132-47 PMID: 21183790
  61. Early progress in epigenetic regulation of endothelin pathway genes.
    Br J Pharmacol. 2013 Jan;168(2):327-34 PMID: 22220553
  62. β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.
    Oncogene. 2013 Oct 17;32(42):5066-77 PMID: 23208497
  63. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
    Cancer Res. 2001 Nov 15;61(22):8340-6 PMID: 11719468
  64. Assessment of endothelin-A receptor expression in subcutaneous and orthotopic thyroid carcinoma xenografts in vivo employing optical imaging methods.
    Endocrinology. 2012 Jun;153(6):2907-18 PMID: 22510270
  65. Polymorphisms in the endothelin-1 and endothelin a receptor genes and survival in patients with locoregionally advanced nasopharyngeal carcinoma.
    Clin Cancer Res. 2011 Apr 15;17(8):2451-8 PMID: 21487064
  66. TLR2 and TLR4 agonists induce production of the vasoactive peptide endothelin-1 by human dendritic cells.
    Mol Immunol. 2009 Sep;46(15):3178-82 PMID: 19559483
  67. Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells.
    Oncogene. 2014 Mar 27;33(13):1725-35 PMID: 23584483
  68. Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth.
    Cancer Res. 1999 Feb 1;59(3):720-7 PMID: 9973223
  69. Endothelin-1 synthesis reduced by red wine.
    Nature. 2001 Dec 20-27;414(6866):863-4 PMID: 11780050
  70. Endothelin receptor A blockade enhances taxane effects in prostate cancer.
    Neoplasia. 2006 Sep;8(9):725-32 PMID: 16984730
  71. Molecular classification of cutaneous malignant melanoma by gene expression profiling.
    Nature. 2000 Aug 3;406(6795):536-40 PMID: 10952317
  72. Endothelin receptor blockade inhibits molecular effectors of Kaposi's sarcoma cell invasion and tumor growth in vivo.
    Am J Pathol. 2003 Aug;163(2):753-62 PMID: 12875994
  73. Expression of endothelin-1 is related to poor prognosis in non-small cell lung carcinoma.
    Eur J Cancer. 2005 Dec;41(18):2828-35 PMID: 16298124
  74. Peripheral endothelin B receptor agonist-induced antinociception involves endogenous opioids in mice.
    Pain. 2010 May;149(2):254-262 PMID: 20206445
  75. Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.
    Cancer Res. 2002 Nov 15;62(22):6381-4 PMID: 12438219
  76. Endothelin-3 is produced by metastatic melanoma cells and promotes melanoma cell survival.
    J Cutan Med Surg. 2008 Mar-Apr;12(2):64-70 PMID: 18346402
  77. Expression of endothelin receptor subtypes in bronchial tumors.
    Oncol Rep. 2010 Feb;23(2):457-63 PMID: 20043107
  78. Knockdown of endothelin A receptor expression inhibits osteosarcoma pulmonary metastasis in an orthotopic xenograft mouse model.
    Mol Med Rep. 2012 Jun;5(6):1391-5 PMID: 22446894
  79. Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes.
    Cancer Res. 2011 Dec 1;71(23):7259-69 PMID: 22006997
  80. Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling.
    Trends Biochem Sci. 2011 Sep;36(9):457-69 PMID: 21764321
  81. Endothelin-1 promotes epithelial-to-mesenchymal transition in human ovarian cancer cells.
    Cancer Res. 2005 Dec 15;65(24):11649-57 PMID: 16357176
  82. Endothelin-1 decreases gap junctional intercellular communication by inducing phosphorylation of connexin 43 in human ovarian carcinoma cells.
    J Biol Chem. 2003 Oct 17;278(42):41294-301 PMID: 12907686
  83. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.
    Cancer. 2004 May 15;100(10):2118-24 PMID: 15139053
  84. beta-Catenin activates the growth factor endothelin-1 in colon cancer cells.
    Oncogene. 2005 Jan 20;24(4):597-604 PMID: 15558022
  85. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells.
    Mol Cancer Res. 2011 Dec;9(12):1668-85 PMID: 22013079
  86. Quantitative analysis of promoter methylation of the EDNRB gene in gastric cancer.
    Med Oncol. 2012 Mar;29(1):107-12 PMID: 21264540
  87. UV-induction of keratinocyte endothelin-1 downregulates E-cadherin in melanocytes and melanoma cells.
    J Clin Invest. 2002 Aug;110(4):443-52 PMID: 12189238
  88. Bombesin and glucocorticoids stimulate human breast cancer cells to produce endothelin, a paracrine mitogen for breast stromal cells.
    Cancer Res. 1992 Apr 1;52(7):1786-90 PMID: 1551109
  89. Role of the endothelin axis and its antagonists in the treatment of cancer.
    Br J Pharmacol. 2011 May;163(2):220-33 PMID: 21232046
  90. Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer.
    Prostate Cancer Prostatic Dis. 2013 Jun;16(2):187-92 PMID: 23381694
  91. A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.
    Mol Cancer. 2010 Mar 30;9:69 PMID: 20350333
  92. Paracrine regulation of ovarian cancer by endothelin.
    Eur J Cancer. 1999 Sep;35(9):1381-7 PMID: 10658531
  93. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice.
    Cell. 1994 Dec 30;79(7):1267-76 PMID: 8001159
  94. Endothelin-1 inhibits apoptosis in prostate cancer.
    Neoplasia. 2005 Jul;7(7):631-7 PMID: 16026642
  95. A novel potent vasoconstrictor peptide produced by vascular endothelial cells.
    Nature. 1988 Mar 31;332(6163):411-5 PMID: 2451132
  96. ZD4054, a specific antagonist of the endothelin A receptor, inhibits tumor growth and enhances paclitaxel activity in human ovarian carcinoma in vitro and in vivo.
    Mol Cancer Ther. 2007 Jul;6(7):2003-11 PMID: 17620430
  97. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma.
    Int J Cancer. 2008 Sep 1;123(5):1126-32 PMID: 18546273
  98. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2.
    Cancer Res. 2005 Aug 15;65(16):7320-7 PMID: 16103083
  99. A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14).
    Gynecol Oncol. 2013 Jul;130(1):31-7 PMID: 23234805
  100. Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis.
    Clin Exp Metastasis. 2006;23(1):41-53 PMID: 16826430
  101. Expression patterns of endothelin-1 and its receptors in colorectal cancer.
    J Surg Oncol. 2012 Jun 1;105(7):643-9 PMID: 22213082
  102. The inhibitory effect of miRNA-1 on ET-1 gene expression.
    FEBS Lett. 2012 Apr 5;586(7):1014-21 PMID: 22569256
  103. Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors.
    Nature. 1996 Feb 8;379(6565):557-60 PMID: 8596637
  104. Modulation of human colon tumor-stromal interactions by the endothelin system.
    Am J Pathol. 2000 Dec;157(6):1863-74 PMID: 11106559
  105. Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy.
    Nat Med. 2008 Jan;14(1):28-36 PMID: 18157142
  106. Aberrant methylation of EDNRB and p16 genes in hepatocellular carcinoma (HCC) in Taiwan.
    Oncol Rep. 2006 Feb;15(2):507-11 PMID: 16391877
  107. Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells.
    Int J Cancer. 2000 Apr 15;86(2):182-7 PMID: 10738244
  108. Expression of the Endothelin-axis in the different histologic subtypes of renal cell carcinoma: a tissue microarray analysis.
    Oncol Rep. 2007 Feb;17(2):275-80 PMID: 17203161
  109. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases.
    Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10954-9 PMID: 12941866
  110. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
    J Urol. 2003 Mar;169(3):1143-9 PMID: 12576870
  111. Role of endothelin-1 in neovascularization of ovarian carcinoma.
    Am J Pathol. 2000 Nov;157(5):1537-47 PMID: 11073813
  112. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma.
    Cancer Res. 2012 Oct 1;72(19):4909-19 PMID: 22865454
  113. Frequent loss of endothelin-3 (EDN3) expression due to epigenetic inactivation in human breast cancer.
    Breast Cancer Res. 2009;11(3):R34 PMID: 19527488
  114. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eur Urol. 2009 Nov;56(5):837-45 PMID: 18945538
  115. Effects of selective endothelin ET(A) receptor antagonists on endothelin-1-induced potentiation of cancer pain.
    Eur J Pharmacol. 2004 May 25;492(2-3):177-82 PMID: 15178362
  116. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
    Cancer. 2008 Nov 1;113(9):2478-87 PMID: 18785254
  117. Endothelin-1 inhibits prolyl hydroxylase domain 2 to activate hypoxia-inducible factor-1alpha in melanoma cells.
    PLoS One. 2010 Jun 21;5(6):e11241 PMID: 20574527
  118. ROCK cooperated with ET-1 to induce epithelial to mesenchymal transition through SLUG in human ovarian cancer cells.
    Biosci Biotechnol Biochem. 2012;76(1):42-7 PMID: 22232246
  119. Inhibitory effect of endothelin A receptor blockade on tumor growth and liver metastasis of a human gastric cancer cell line.
    Gastric Cancer. 2007;10(2):123-8 PMID: 17577623
  120. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.
    Clin Cancer Res. 2011 Apr 15;17(8):2350-60 PMID: 21220476
  121. Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases.
    Carcinogenesis. 2004 Aug;25(8):1543-9 PMID: 15044327
  122. Endothelin-3 growth factor levels decreased in cervical cancer compared with normal cervical epithelial cells.
    Hum Pathol. 2007 Jul;38(7):1047-1056 PMID: 17445867
  123. A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis.
    Cancer Res. 2008 Sep 15;68(18):7293-303 PMID: 18794116
  124. Distinct patterns of endothelin axis expression in primary prostate cancer.
    Urology. 2007 Jul;70(1):209-15 PMID: 17656249
  125. Positive inter-regulation between beta-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells.
    Mol Pharmacol. 2006 Feb;69(2):520-31 PMID: 16291872
  126. Expression and localization of endothelin-1 and endothelin receptors in human meningiomas. Evidence for a role in tumoral growth.
    J Clin Invest. 1995 Oct;96(4):2017-25 PMID: 7560095
  127. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence.
    Br J Cancer. 2005 Jun 20;92(12):2148-52 PMID: 15956965
  128. Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study.
    Mol Cancer Ther. 2013 Aug;12(8):1556-67 PMID: 23723122
  129. Endothelin B receptor, a new target in cancer immune therapy.
    Clin Cancer Res. 2009 Jul 15;15(14):4521-8 PMID: 19567593
  130. Mesenchymal stem cells promote growth and angiogenesis of tumors in mice.
    Oncogene. 2013 Sep 12;32(37):4343-54 PMID: 23085755
  131. Epigenetic inactivation of endothelin-2 and endothelin-3 in colon cancer.
    Int J Cancer. 2013 Mar 1;132(5):1004-12 PMID: 22865632
  132. Function and survival of dendritic cells depend on endothelin-1 and endothelin receptor autocrine loops.
    Blood. 2004 Oct 1;104(7):2107-15 PMID: 15213100
  133. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits.
    Nat Rev Cancer. 2009 Apr;9(4):265-73 PMID: 19262571
  134. Detection of previously unidentified metastatic disease as a leading cause of screening failure in a phase III trial of zibotentan versus placebo in patients with nonmetastatic, castration resistant prostate cancer.
    J Urol. 2012 Jul;188(1):103-9 PMID: 22583636
  135. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.
    Mol Endocrinol. 2007 Feb;21(2):486-98 PMID: 17068196
  136. Endothelin-2, the forgotten isoform: emerging role in the cardiovascular system, ovarian development, immunology and cancer.
    Br J Pharmacol. 2013 Jan;168(2):283-95 PMID: 22118774
  137. Endothelin-2 deficiency causes growth retardation, hypothermia, and emphysema in mice.
    J Clin Invest. 2013 Jun;123(6):2643-53 PMID: 23676500
  138. The endothelin axis: emerging role in cancer.
    Nat Rev Cancer. 2003 Feb;3(2):110-6 PMID: 12563310
  139. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells.
    Cancer Res. 2000 Sep 15;60(18):5310-7 PMID: 11016663
  140. Endothelin-1 stimulates colon cancer adjacent fibroblasts.
    Int J Cancer. 2012 Mar 15;130(6):1264-72 PMID: 21445967
  141. Activation of mitogenic signaling by endothelin 1 in ovarian carcinoma cells.
    Cancer Res. 1997 Apr 1;57(7):1306-11 PMID: 9102218
  142. Endothelin-2 is upregulated in basal cell carcinoma under control of Hedgehog signaling pathway.
    Biochem Biophys Res Commun. 2010 Jan 1;391(1):486-91 PMID: 19914214
  143. Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1alpha in ovarian carcinoma cells.
    J Biol Chem. 2002 Aug 2;277(31):27850-5 PMID: 12023962
  144. Role of endothelin receptor signalling in squamous cell carcinoma.
    Int J Oncol. 2012 Apr;40(4):1011-9 PMID: 22075705
  145. Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ.
    Br J Cancer. 2005 May 9;92(9):1720-8 PMID: 15841074
  146. Targeting the endothelin axis with atrasentan, in combination with IFN-alpha, in metastatic renal cell carcinoma.
    Br J Cancer. 2012 Jan 17;106(2):284-9 PMID: 22215065
  147. Endothelin-1 promotes MMP-13 production and migration in human chondrosarcoma cells through FAK/PI3K/Akt/mTOR pathways.
    J Cell Physiol. 2012 Aug;227(8):3016-26 PMID: 21959927
  148. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone.
    Cancer. 2012 Nov 15;118(22):5709-18 PMID: 22786751
  149. Inhibition of cyclooxygenase-1 and -2 expression by targeting the endothelin a receptor in human ovarian carcinoma cells.
    Clin Cancer Res. 2004 Jul 15;10(14):4670-9 PMID: 15269139
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc3546
Published
2013-09-00
Epub
2013-00-25
Pages
637-51
Language
English
Region
England
NLM ID
101124168
Subset
IM
External Links
PubMed source DOI: 10.1038/nrc3546 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2